Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Location: United States, North Carolina, Durham
Employees: 51-200
Phone: +1 919-313-9633
Total raised: $212M
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | First In V... | firstinven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.04.2021 | - | $50M | - |
| 20.10.2015 | Series B | $150M | - |
| 08.09.2010 | - | $12M | - |
Mentions in press and media 22
| Date | Title | Description |
| 04.10.2024 | Humacyte Announces Pricing of $30.0 Million Registered Direct Offering | DURHAM, N.C., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it enter... |
| 01.03.2024 | Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock | DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced today announc... |
| 29.02.2024 | Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock | - |
| 25.06.2023 | How surgeons in Ukraine are saving soldiers' lives with a simple tube grown from human cells | The human acellular vessel could replace traditional methods of treating traumatic vascular injuries. Humacyte Redeem now Some Ukrainian surgeons are using cutting-edge medical technology to treat wounded soldiers. The medical device is a h... |
| 30.03.2023 | 🎥 Cultivated meat startup Myodenovo emerges from stealth, focuses on whole cuts to reach ‘diehard meat lovers’ | “To get really diehard meat lovers to transition to cultivated meat, it’s going to need to be really close to the real thing,” says the founder and CEO of Myodenovo, a US-based startup emerging from stealth with a mission to create thick, w... |
| 14.04.2021 | Humacyte Receives $50M Debt Facility From Silicon Valley Bank | Humacyte, Inc., a Durham, N.C.-based clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, closed a secured debt financing facility with Silicon Valley Bank for up t... |
| 20.08.2018 | Kidney disease is a killer. More precise classification can help tame it | Kidney disease, once commonly thought of as a single entity, has become far more complicated. That’s a good thing, because it opens the door for better and more precise treatments. Back in 2002, the National Kidney Foundation published the ... |
| 12.06.2018 | Term Sheet — Tuesday, June 12 | MOVING ON Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop If you are one of these investors or if you have more information about this, please send info my way. Here is Term Sheet’s anonymous... |
| 11.03.2018 | Humacyte Closes $75 Million Series C Financing | RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Humacyte, an innovator in biotechnology and regenerative medicine, announced today that the company raised $75 million in a Series C preferred stock financing, led by a global consortium of exi... |
| 09.03.2018 | Durham-based Humacyte Raises $75M | Humacyte Inc., a biotechnology company, has raised $75 million, according to a filing Friday with the Securities and Exchange Commission. The money was raised in the form of equity from 29 investors, according to the filing. The company did... |
Show more